Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers : a phase 1 trial
- Author
- Cassandra Aldrich, Isabel Leroux-Roels (UGent) , Katell Bidet Huang, Mihai Alexandru Bica, Edde Loeliger, Oliver Schoenborn-Kellenberger, Lisa Walz, Geert Leroux-Roels (UGent) , Frank von Sonnenburg and Lidia Oostvogels
- Organization
- Keywords
- Vaccine, mRNA, Lipid nanoparticles, Rabies
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 743.11 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8759360
- MLA
- Aldrich, Cassandra, et al. “Proof-of-Concept of a Low-Dose Unmodified MRNA-Based Rabies Vaccine Formulated with Lipid Nanoparticles in Human Volunteers : A Phase 1 Trial.” VACCINE, vol. 39, no. 8, 2021, pp. 1310–18, doi:10.1016/j.vaccine.2020.12.070.
- APA
- Aldrich, C., Leroux-Roels, I., Huang, K. B., Bica, M. A., Loeliger, E., Schoenborn-Kellenberger, O., … Oostvogels, L. (2021). Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers : a phase 1 trial. VACCINE, 39(8), 1310–1318. https://doi.org/10.1016/j.vaccine.2020.12.070
- Chicago author-date
- Aldrich, Cassandra, Isabel Leroux-Roels, Katell Bidet Huang, Mihai Alexandru Bica, Edde Loeliger, Oliver Schoenborn-Kellenberger, Lisa Walz, Geert Leroux-Roels, Frank von Sonnenburg, and Lidia Oostvogels. 2021. “Proof-of-Concept of a Low-Dose Unmodified MRNA-Based Rabies Vaccine Formulated with Lipid Nanoparticles in Human Volunteers : A Phase 1 Trial.” VACCINE 39 (8): 1310–18. https://doi.org/10.1016/j.vaccine.2020.12.070.
- Chicago author-date (all authors)
- Aldrich, Cassandra, Isabel Leroux-Roels, Katell Bidet Huang, Mihai Alexandru Bica, Edde Loeliger, Oliver Schoenborn-Kellenberger, Lisa Walz, Geert Leroux-Roels, Frank von Sonnenburg, and Lidia Oostvogels. 2021. “Proof-of-Concept of a Low-Dose Unmodified MRNA-Based Rabies Vaccine Formulated with Lipid Nanoparticles in Human Volunteers : A Phase 1 Trial.” VACCINE 39 (8): 1310–1318. doi:10.1016/j.vaccine.2020.12.070.
- Vancouver
- 1.Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers : a phase 1 trial. VACCINE. 2021;39(8):1310–8.
- IEEE
- [1]C. Aldrich et al., “Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers : a phase 1 trial,” VACCINE, vol. 39, no. 8, pp. 1310–1318, 2021.
@article{8759360,
author = {{Aldrich, Cassandra and Leroux-Roels, Isabel and Huang, Katell Bidet and Bica, Mihai Alexandru and Loeliger, Edde and Schoenborn-Kellenberger, Oliver and Walz, Lisa and Leroux-Roels, Geert and von Sonnenburg, Frank and Oostvogels, Lidia}},
issn = {{0264-410X}},
journal = {{VACCINE}},
keywords = {{Vaccine,mRNA,Lipid nanoparticles,Rabies}},
language = {{eng}},
number = {{8}},
pages = {{1310--1318}},
title = {{Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers : a phase 1 trial}},
url = {{http://doi.org/10.1016/j.vaccine.2020.12.070}},
volume = {{39}},
year = {{2021}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: